Zepp Health Corporation Q1 2026 Earnings Recap

Zepp Health’s shares plunged 28.8% following the quarter as investors were clearly disappointed by the company’s cautious outlook and signs of deceleration embedded in the commentary, outweighing reported revenue growth and margin expansion.

Key Takeaways

• Amazfit branded revenue grew 33.8% year-over-year in Q1, driven by new premium product launches amid a seasonally soft quarter.
• The company highlighted a meaningful shift toward higher-priced premium models, with roughly 50% of T-Rex family sales at $399 and $549 tiers, lifting average selling price by over 20% year-over-year.
• Gross margins expanded despite inflationary pressures on memory and storage costs, attributed to improved product mix and cost discipline.
• Management emphasized a strategic pivot toward “hybrid training” positioning and deeper integration with HYROX, targeting serious athletes beyond casual users.
• However, the stock reaction suggests skepticism about the sustainability of growth, potential margin headwinds ahead, or tempered guidance alluded to in management’s commentary.